

**From:** [REDACTED]  
**To:** [REDACTED]  
**Subject:** RE: Cost Basis  
**Date:** Tuesday, October 10, 2017 2:26:08 PM

---

*OK... That's what they reported to us. Let me know if there's anything else I can support you with.*

---

**From:** Richard Kahn [mailto:[REDACTED]]  
**Sent:** Tuesday, October 10, 2017 1:17 PM  
**To:** Otoy, Rafael C  
**Cc:** Paul Barrett  
**Subject:** Re: Cost Basis

Cost basis of securities transferred in are as follows:  
Thank you

<b>Asset Description</b>	<b>Purchase Date</b>	<b>Quantity</b>	<b>Cost</b>
Ascena Retail Group Inc. (Formerly Dress Barn 1.3.11)	1/16/01	70,500	1,500,000
Foundation Medicine Inc	1/16/14	49,830	1,265,037
Sangamo Therapeutics Inc	5/28/13	50,000	422,214

Richard Kahn  
HBRK Associates Inc.  
575 Lexington Avenue, 4th Floor  
New York, NY 10022

[REDACTED]  
[REDACTED]  
[REDACTED]

On Oct 10, 2017, at 2:09 PM, <[REDACTED]>  
<[REDACTED]> wrote:

**CONFIDENTIAL**

SDNY\_GM\_00012330

EFTA\_00122979

EFTA01268401

Hello, Richard. I wanted to follow up with you. My understanding is that there may be some questions around cost basis for the assets that you transferred over. How may I support you?

<image003.jpg>

**CONFIDENTIAL**

SDNY\_GM\_00012331

EFTA\_00122980

EFTA01268402